Prognostic Factors in Ewing's Tumours and Peripheral Neuroectodermal Tumours
Author Information
Author(s): Oberlin O, Deley M C Le, Bui B N'Guyen, Gentet J C, Philip T, Terrier P, Carrie C, Mechinaud F, Schmitt C, Babin-Boillettot A, Michon J
Primary Institution: Institut Gustave Roussy
Hypothesis
Can early prognostic factors improve survival rates in patients with Ewing's sarcoma or peripheral neuroectodermal tumours?
Conclusion
Therapeutic trials for localized Ewing's sarcoma should focus on the histological response to chemotherapy or tumor volume based on the treatment modality.
Supporting Evidence
- The projected overall survival at 5 years was 66%.
- Disease-free survival (DFS) was 58%.
- 75% DFS for patients with a good histological response to chemotherapy.
- 48% DFS for intermediate responders.
- 20% DFS for poor responders.
Takeaway
Doctors want to find out how to help kids with a type of cancer called Ewing's sarcoma live longer and healthier by looking at how their tumors respond to treatment.
Methodology
Patients received semi-continuous chemotherapy followed by surgery when possible, with maintenance chemotherapy over 10 months.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website